Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ORGO with free AI briefings, catalyst countdowns, and dilution alerts.

ORGO · Organogenesis Holdings Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$21.3M Cash on Hand
2.5mo Cash Runway
Follow ORGO by email Get an email when ORGO reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ORGO, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
CelTx™ Gingival Recession N/A · NCT01134081 Completed
Amniotic Suspension Allograft Knee Osteoarthritis Phase 3 · NCT06000410 Completed
Gintuit Edentulous Alveolar Ridge Phase 1/2 · NCT01929954 Terminated

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ORGO holds $21.3M in cash and short-term investments (as of Sep 30, 2026) and burns about $25.1M/quarter from operations, an estimated runway of 2.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ORGO files for a raise →

👥 Who Owns ORGO

Insiders 16.9% Other 5%+ holders 17.2% Institutions (171 holders) 50.8% Public and other holders 15.1%
HolderTypeShares% of sharesAs of
Alan A. Ades 5%+ holder (13D) 22,319,836 17.20% 2025-06-24
Glenn H Nussdorf
Director
Insider 11,748,560 9.05% 2025-12-16
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 9,985,951 7.69% 2025-12-31
Gary S. Gillheeney
President and CEO, Director · +507,795 options
Insider 4,232,087 3.26% 2026-02-18
Patrick Bilbo
Chief Operating Officer · +120,267 options
Insider 1,128,312 0.87% 2026-02-18
Lori Freedman
Chief Admin. and Legal Officer · +115,812 options
Insider 1,023,643 0.79% 2026-02-18
Brian Grow
Chief Commercial Officer · +133,630 options
Insider 899,724 0.69% 2026-02-18
David Francisco
Chief Financial Officer · +111,358 options
Insider 731,312 0.56% 2026-02-18
Arthur S Leibowitz
Director
Insider 291,014 0.22% 2026-03-09
Robert Cavorsi
Vice President, Strategy · +53,452 options
Insider 275,524 0.21% 2026-03-01
Prathyusha Duraibabu
Director
Insider 247,047 0.19% 2026-02-18
Jon L Giacomin
Director
Insider 241,026 0.19% 2026-02-18

Share count 129,801,720 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ORGO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ORGO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.